A Near-Infrared Photoimmunotherapy Technique to Treat Lung Cancer in a Murine Model
Transkript
Take an immunodeficient mouse that exhibits tumor growth in the pleura, a double-layered membrane lining the chest cavity.
The engineered tumor cells express the enzyme luciferase.
Intravenously inject an antibody-photosensitizer conjugate, or APC, comprising a tumor antigen-specific antibody bound to a photoabsorber dye.
The control tumor-bearing mouse does not receive the injection.
In the treated mouse, APCs reach the pleural cavity and bind to tumor cell-surface antigens.
Anesthetize the mouse and expose the chest to near-infrared radiation.
Radiation-induced dye photolysis changes the APC shape, inducing stress and increasing transmembrane water flow, resulting in tumor cell bursting and necrotic death.
In the control mouse, tumor cells remain unaffected.
Intraperitoneally inject the bioluminescent substrate luciferin. Upon entering viable tumor cells, luciferin gets oxidized by luciferase, emitting light.
Measure the bioluminescence at predetermined intervals.
A decreased bioluminescence in the treated mouse compared to the increased bioluminescence in the control mouse from tumor growth confirms photoimmunotherapy-mediated tumor destruction.
